Abstract
Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity. The median nadir leukocyte count was 1.75 cells/mm3, neutrophil count was 1.55 cells/mm3, hemoglobin was 8.75 gm/dl, and platelet count was 20,500 cells/mm3. Topotecan is not efficacious in the treatment of cisplatin-refractory GCT.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / adverse effects
-
Camptothecin / analogs & derivatives*
-
Camptothecin / therapeutic use
-
Cisplatin / therapeutic use
-
Drug Resistance, Neoplasm
-
Drugs, Investigational / administration & dosage
-
Drugs, Investigational / adverse effects
-
Drugs, Investigational / therapeutic use*
-
Female
-
Germinoma / drug therapy*
-
Germinoma / secondary
-
Hemoglobins / metabolism
-
Humans
-
Leukocyte Count / drug effects
-
Male
-
Middle Aged
-
Neutrophils / cytology
-
Neutrophils / drug effects
-
Platelet Count / drug effects
-
Topotecan
Substances
-
Antineoplastic Agents
-
Drugs, Investigational
-
Hemoglobins
-
Topotecan
-
Cisplatin
-
Camptothecin